Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

This article was originally published here

The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.

The post Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply